RESISTANCE TO 1-[(2-HYDROXYETHOXY)METHYL]-6-(PHENYLTHIO)THYMINE DERIVATIVES IS GENERATED BY MUTATIONS AT MULTIPLE SITES IN THE HIV-1 REVERSE-TRANSCRIPTASE

被引:35
作者
BUCKHEIT, RW
FLIAKASBOLTZ, V
YEAGYBARGO, S
WEISLOW, O
MAYERS, DL
BOYER, PL
HUGHES, SH
PAN, BC
CHU, SH
BADER, JP
机构
[1] SPA TECHNOL INC,ROCKVILLE,MD 20850
[2] WALTER REED ARMY INST RES,DEPT HIV DIS PREVENT,ROCKVILLE,MD 20850
[3] NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,FREDERICK,MD 21702
[4] BROWN UNIV,DIV BIOL & MED,PROVIDENCE,RI 02912
[5] NCI,DIV CANC TREATMENT,DEV THERAPEUT PROGRAM,ANTIVIRAL EVALUAT BRANCH,BETHESDA,MD 20892
关键词
D O I
10.1006/viro.1995.1330
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Virus isolates resistant to 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) and a highly potent HEPT derivative, [1-benzyloxymethyl-5-ethyl-6-(alpha-pyridylthio)uracil] (NSC 648400, E-BPTU), were selected in cell culture. Cross-resistance evaluation indicated that the two drug-resistant virus isolates were phenotypically distinct from one another although each of the virus isolates was resistant to both of the HEPT derivatives. The virus isolate resistant to NSC 648400 had a single amino acid change in the reverse transcriptase (Y181C) which resulted in cross-resistance to all of the nonnucleoside reverse transcriptase inhibitors evaluated, with the exception of calanolide A. The NSC 648400-resistant virus isolate exhibited 15-fold enhanced sensitivity to calanolide A. The virus isolate selected in the presence of HEPT exhibited a single amino acid change (P236L) which was not cross-resistant to other nonnucleoside RT inhibitors tested with the exception of the two HEPT derivatives. This HEPT-resistant virus isolate exhibited enhanced sensitivity (5- to 10-fold) to thiazolobenzimidazole. We have used both virus isolates with defined single amino acid changes in the RT and bacterially expressed RTs with site-directed amino acid substitutions to test the effects of a wide variety of mutations on the activity of NSC 648400. Single mutations at amino acids 101, 103, 106, 181, or 236 yielded virus with high resistance (> 20)-fold) to NSC 648400, while lower levels of resistance were seen with mutations at amino acids 98, 100, or 108. These results suggest that several changes in the conformation of the nonnucleoside inhibitor binding site of the HIV-1 reverse transcriptase can affect the inhibitory activity of the HEPT class of compounds. (C) 1995 academic Press, Inc.
引用
收藏
页码:186 / 193
页数:8
相关论文
共 40 条
[1]   PRECLINICAL EVALUATION OF MKC-442, A HIGHLY POTENT AND SPECIFIC INHIBITOR OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 IN-VITRO [J].
BABA, M ;
SHIGETA, S ;
YUASA, S ;
TAKASHIMA, H ;
SEKIYA, K ;
UBASAWA, M ;
TANAKA, H ;
MIYASAKA, T ;
WALKER, RT ;
DECLERCQ, E .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (04) :688-692
[2]   HIGHLY SPECIFIC-INHIBITION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 BY A NOVEL 6-SUBSTITUTED ACYCLOURIDINE DERIVATIVE [J].
BABA, M ;
TANAKA, H ;
DECLERCQ, E ;
PAUWELS, R ;
BALZARINI, J ;
SCHOLS, D ;
NAKASHIMA, H ;
PERNO, CF ;
WALKER, RT ;
MIYASAKA, T .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1989, 165 (03) :1375-1381
[3]   OXATHIIN CARBOXANILIDE, A POTENT INHIBITOR OF HUMAN-IMMUNODEFICIENCY-VIRUS REPRODUCTION [J].
BADER, JP ;
MCMAHON, JB ;
SCHULTZ, RJ ;
NARAYANAN, VL ;
PIERCE, JB ;
HARRISON, WA ;
WEISLOW, OS ;
MIDELFORT, CF ;
STINSON, SF ;
BOYD, MR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (15) :6740-6744
[4]   TREATMENT OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1)-INFECTED CELLS WITH COMBINATIONS OF HIV-1-SPECIFIC INHIBITORS RESULTS IN A DIFFERENT RESISTANCE PATTERN THAN DOES TREATMENT WITH SINGLE-DRUG THERAPY [J].
BALZARINI, J ;
KARLSSON, A ;
PEREZPEREZ, MJ ;
CAMARASA, MJ ;
TARPLEY, WG ;
DECLERCQ, E .
JOURNAL OF VIROLOGY, 1993, 67 (09) :5353-5359
[5]   KNOCKING-OUT CONCENTRATIONS OF HIV-1-SPECIFIC INHIBITORS COMPLETELY SUPPRESS HIV-1 INFECTION AND PREVENT THE EMERGENCE OF DRUG-RESISTANT VIRUS [J].
BALZARINI, J ;
KARLSSON, A ;
PEREZPEREZ, MJ ;
CAMARASA, MJ ;
DECLERCQ, E .
VIROLOGY, 1993, 196 (02) :576-585
[6]   HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1) STRAINS SELECTED FOR RESISTANCE AGAINST THE HIV-1-SPECIFIC [2',5'-BIS-O-(TERT-BUTYLDIMETHYLSILYL)-3'-SPIRO-5''-(4''-AMINO-1'',2''-OXATHIOLE-2'',2''-DIOXIDE)]-BETA-D-PENTOFURANOSYL (TSAO) NUCLEOSIDE ANALOGS RETAIN SENSITIVITY TO HIV-1-SPECIFIC NONNUCLEOSIDE INHIBITORS [J].
BALZARINI, J ;
KARLSSON, A ;
VANDAMME, AM ;
PEREZPEREZ, MJ ;
ZHANG, H ;
VRANG, L ;
OBERG, B ;
BACKBRO, K ;
UNGE, T ;
SANFELIX, A ;
VELAZQUEZ, S ;
CAMARASA, MJ ;
DECLERCQ, E .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (15) :6952-6956
[7]  
BALZARINI J, 1993, MOL PHARMACOL, V44, P694
[8]   ANALYSIS OF NONNUCLEOSIDE DRUG-RESISTANT VARIANTS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REVERSE-TRANSCRIPTASE [J].
BOYER, PL ;
CURRENS, MJ ;
MCMAHON, JB ;
BOYD, MR ;
HUGHES, SH .
JOURNAL OF VIROLOGY, 1993, 67 (04) :2412-2420
[9]   DIFFERENTIAL ANTIVIRAL ACTIVITY OF 2 TIBO DERIVATIVES AGAINST THE HUMAN IMMUNODEFICIENCY AND MURINE LEUKEMIA VIRUSES ALONE AND IN COMBINATION WITH OTHER ANTI-HIV AGENTS [J].
BUCKHEIT, RW ;
GERMANYDECKER, J ;
HOLLINGSHEAD, MG ;
ALLEN, LB ;
SHANNON, WM ;
JANSSEN, PAJ ;
CHIRIGOS, MA .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1993, 9 (11) :1097-1106
[10]   COMPARITIVE ANTI-HIV EVALUATION OF DIVERSE HIV-1-SPECIFIC REVERSE-TRANSCRIPTASE INHIBITOR-RESISTANT VIRUS ISOLATES DEMONSTRATES THE EXISTENCE OF DISTINCT PHENOTYPIC SUBGROUPS [J].
BUCKHEIT, RW ;
FLIAKASBOLTZ, V ;
DECKER, WD ;
ROBERSON, JL ;
STUP, TL ;
PYLE, CA ;
WHITE, EL ;
MCMAHON, JB ;
CURRENS, MJ ;
BOYD, MR ;
BADER, JP .
ANTIVIRAL RESEARCH, 1995, 26 (02) :117-132